Roche Holding | ROG - Operating Profit


Roche Holding reported CHF9.56B in Operating Profit for its fiscal semester ending in December of 2025.





Operating Profit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Alcon AG USD 297M 16M Mar/2026
Almirall EUR 30.23M 12.8M Dec/2025
Amgen USD 3.83B 130M Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
Bayer EUR 3.53B 2.42B Mar/2026
Biogen USD 514.3M 128.8M Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Fresenius EUR 713M 139M Dec/2025
Fresenius Medical Care EUR 268M 395M Mar/2026
Genmab DKK 260M 199M Dec/2025
Gilead Sciences USD 2.68B 284M Mar/2026
GlaxoSmithKline GBP 2.29B 856M Mar/2026
GRIFOLS EUR 249M 26.38M Mar/2026
Hikma Pharmaceutical USD 348M 161M Dec/2025
Lakefront Biotherapeutics EUR -63.7M 844.26M Mar/2026
Lonza CHF 673M 243M Jun/2025
Merck EUR 1.05B 572M Mar/2026
Merck USD -1.88B 8.12B Mar/2026
Novartis USD 4.24B 171M Mar/2026
Orion EUR 114.8M 213.4M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Philips EUR 302M 417M Mar/2026
Recordati EUR 231.11M 47.11M Mar/2026
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.94B 239M Mar/2026
UCB EUR 1.29B 571M Dec/2025